A New Light at the End of the Idiopathic Hypersomnia Tunnel

A New Light at the End of the Idiopathic Hypersomnia Tunnel

By: Sam Kashani, MD, FAASM In August 2021, Jazz Pharmaceuticals announced the US FDA approval of Xywav for the treatment of idiopathic hypersomnia in adults. Xywav, an oral solution consisting primarily of oxybate (GHB), already has approval for the treatment of...
Circadian Issues in the Sleep Doctor’s Office

Circadian Issues in the Sleep Doctor’s Office

By: Andrew Binder, MD, FAASM, FCCP I love being a sleep doctor. I often introduce myself as a “recovering pulmonary and critical care doctor.”  One of the reasons I love being a sleep doctor is that I think it is one of the few things, in my advanced age, at which I...
OSA and Physician’s Role in Weight Loss

OSA and Physician’s Role in Weight Loss

By: Said Mostafavi, MD, FCCP, FAASM Like most sleep physicians, treating sleep-disordered breathing constitutes a large percentage of my practice. When it comes to treating obstructive sleep apnea, we thankfully have various treatment options available, some...

Philips Respironics Recall of PAP devices

Dear CSS Members: You may be aware of the Phillips recall of certain PAP devices.  We understand that this recall has placed a burden on sleep center staff and patients alike. From various sources, the CSS has gathered an array of information regarding the recall and...